Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dror Michaelson

Showing results (31-40 of 121) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinomaCedric de Bazelaire, David C Alsop, Daniel George, et al.
European Radiology|April 4, 2006
Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancementCedric de Bazelaire, Neil M Rofsky, Guillaume Duhamel, et al.
Prostate Cancer and Prostatic Diseases|May 19, 2021
Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancerDaniel E Lage, M Dror Michaelson, Richard J Lee, et al.
Immunotherapy|January 30, 2020
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinomaApoorva Ambavane, Shuo Yang, Michael B Atkins, et al.
Journal of the American Society of Nephrology : JASN|March 4, 2005
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinomaWon K Han, Anwar Alinani, Chin-Lee Wu, et al.
Cancer Chemotherapy and Pharmacology|November 6, 2013
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)Ana M Molina, Thomas E Hutson, James Larkin, et al.
Cancer|December 20, 2002
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumorsM Dror Michaelson, David P Ryan, Charles S Fuchs, et al.
JCO Oncology Practice|February 2, 2021
Dana-Farber Cancer Institute/Mass General Brigham Fellowship Response to the COVID-19 PandemicRobert M Stern, M Dror Michaelson, Erica L Mayer, et al.
Urologic Oncology|January 9, 2014
Prognostic significance of indeterminate lung nodules in renal cell carcinomaRena Xu, Nora Horick, Francis J McGovern, et al.
Journal of Translational Medicine|July 4, 2007
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteinsSamuel E Deprimo, Carlo L Bello, John Smeraglia, et al.
Pageof 13

Showing results (31-40 of 121) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinomaCedric de Bazelaire, David C Alsop, Daniel George, et al.
European Radiology|April 4, 2006
Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancementCedric de Bazelaire, Neil M Rofsky, Guillaume Duhamel, et al.
Prostate Cancer and Prostatic Diseases|May 19, 2021
Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancerDaniel E Lage, M Dror Michaelson, Richard J Lee, et al.
Immunotherapy|January 30, 2020
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinomaApoorva Ambavane, Shuo Yang, Michael B Atkins, et al.
Journal of the American Society of Nephrology : JASN|March 4, 2005
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinomaWon K Han, Anwar Alinani, Chin-Lee Wu, et al.
Cancer Chemotherapy and Pharmacology|November 6, 2013
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)Ana M Molina, Thomas E Hutson, James Larkin, et al.
Cancer|December 20, 2002
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumorsM Dror Michaelson, David P Ryan, Charles S Fuchs, et al.
JCO Oncology Practice|February 2, 2021
Dana-Farber Cancer Institute/Mass General Brigham Fellowship Response to the COVID-19 PandemicRobert M Stern, M Dror Michaelson, Erica L Mayer, et al.
Urologic Oncology|January 9, 2014
Prognostic significance of indeterminate lung nodules in renal cell carcinomaRena Xu, Nora Horick, Francis J McGovern, et al.
Journal of Translational Medicine|July 4, 2007
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteinsSamuel E Deprimo, Carlo L Bello, John Smeraglia, et al.
Pageof 13